Cue Biopharma vs Zymeworks
Zymeworks is the larger business, with $106m of revenue in fiscal 2025 against $27.5m for Cue Biopharma (3.9 times as much). Cue Biopharma grew faster (195.7% against 38.9%). Zymeworks kept more of each dollar of sales as profit: a net margin of -76.6% against -96.9%.
| Latest fiscal year | Cue BiopharmaCUE, 2025 | ZymeworksZYME, 2025 |
|---|---|---|
| Revenue | $27.5m | $106m |
| Revenue growth | 195.7% | 38.9% |
| Net income | −$26.6m | −$81.1m |
| Operating margin | — | -87.3% |
| Net margin | -96.9% | -76.6% |
| Return on equity | -121.1% | -26.7% |
| Free cash flow | −$21.9m | −$34.5m |
| Cash | $27.1m | $41.2m |
| Total debt | — | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $41.7m |
| Employees | 29 | 264 |
| Market value | $106m | $2.16bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 5 buys, 15 sales | 0 buys, 11 sales |